Efgartigimod shows potential as maintenance therapy for iTTP in pilot study
A pilot study indicates that efgartigimod may effectively increase ADAMTS13 activity in patients with iTTP, potentially preventing relapses.
Phase III
Hematology / Autoimmune Disorders
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The pilot study results for efgartigimod suggest a promising new maintenance therapy for iTTP, which could shift treatment paradigms in this space. As the market is currently dominated by rituximab, the potential approval of efgartigimod warrants close monitoring of further studies and regulatory developments.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results from larger efficacy studies and any regulatory developments regarding efgartigimod.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.